Dergiler / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 6

Relationship between metabolic syndrome and epicardial fat tissue thickness in patients with chronic obstructive pulmonary disease

Sayfa
405–411
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Early diagnosis of patients at risk of MS may help to prevent ischemic heart disease in these patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: An increase in epicardial fat tissue (EFT) thickness was found to be associated with metabolic syndrome (MS) and ischemic heart disease.
📊
Temel Bulgular & Veri:The aim of our study was to investigate the usefulness of EFT thickness to predict MS in COPD patients.Methods: COPD patients admitted to our clinic during January-December 2014 and healthy controls were included in this prospective casecontrol study.
💡
Sonuç & Katkı:Early diagnosis of patients at risk of MS may help to prevent ischemic heart disease in these patients.
🔬Tür:Araştırma Makalesi
📍Kapsam:2014 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: An increase in epicardial fat tissue (EFT) thickness was found to be associated with metabolic syndrome (MS) and ischemic heart disease. MS is a comorbidity of chronic obstructive pulmonary disease (COPD) resulting from the accompanying systemic inflammation. The aim of our study was to investigate the usefulness of EFT thickness to predict MS in COPD patients.Methods: COPD patients admitted to our clinic during January-December 2014 and healthy controls were included in this prospective casecontrol study. Patients with comorbidities, COPD exacerbation, and malignancies were excluded. Patients and controls were compared in terms of anthropometric measurements, MS-related examination and laboratory findings, pulmonary function tests, and EFT thickness. The correlations between EFT thickness and markers of MS in COPD were evaluated using the Student's t-test and logistic regression analysis.Results: COPD patients and controls were composed of 82 and 84 individuals, respectively. MS was diagnosed in 31 (37.8%) COPD patients. The EFT thickness was significantly higher in COPD patients than in the controls and was also higher in COPD patients with MS than in those without MS (all p<0.001). Each 1-mm increment of EFT raised the risk of MS two-fold (p=0.011, OR=2.08, 95% CI: 1.18-3.68). Increase in triglyceride level (p=0.004, OR=1.02, 95% CI: 1.01-1.03) and reduction in forced vital capacity (p=0.025, OR=0.26, 95% CI: 0.08-0.84) were found to be associated with increased MS risk. The cut-off value for EFT thickness in the prediction of MS in COPD patients was 6.75 mm (sensitivity: 83%, specificity: 65%).Conclusion: EFT thickness is a non-invasive and easily available parameter, which is valuable in the prediction of increased MS risk in COPD patients. Early diagnosis of patients at risk of MS may help to prevent ischemic heart disease in these patients.

🔖

Bu Makaleye Atıf Yap

DEMİR, M., ACET, H., KAYA, H., TAYLAN, M., YÜKSEL, M., YILMAZ, S., SEZGİ, C., KARADENİZ, G., YENİBERTİZ, D. (2016). Relationship between metabolic syndrome and epicardial fat tissue thickness in patients with chronic obstructive pulmonary disease. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 6, 405–411. https://ajindex.com/articles/366746

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Barreiro E, Criner GJ. Update in chronic obstructive pulmonary disease 2013. Am J Respir Crit Care Med 2014; 189: 1337-44
  2. Garcia-Rio F, Miravitlles M, Soriano JB, Munoz L, Duran-Tauleria E, Sanchez G, et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir Res 2010; 11: 63
  3. Agusti A, Edwards LD, Rennard SI, Mac Nee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7: e37483
  4. Groenewegen KH, Postma DS, Hop WC, Wielders PL, Schlosser NJ, Wouters EF. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133: 350-7
  5. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80
  6. Ormseth MJ, Lipson A, Alexopoulos N, Hartlage GR, Oeser AM, Bian A, et al. Association of epicardial adipose tissue with cardiometabolic risk and metabolic syndrome in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 1410-5
  7. Lipson A, Alexopoulos N, Hartlage GR, Arepalli C, Oeser A, Bian A, et al. Epicardial adipose tissue is increased in patients with systemic lupus erythematosus. Atherosclerosis 2012; 223: 389-93
  8. Breyer MK, Spruit MA, Hanson CK, Franssen FM, Vanfleteren LE, Groenen MT, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014; 9: e98013
  9. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005; 2: 536-43
  10. Pierdomenico SD, Pierdomenico AM, Cuccurullo F, Iacobellis G. Meta-analysis of the relation of echocardiographic epicardial adipose tissue thickness and the metabolic syndrome. Am J Cardiol 2013; 111: 73-8
  11. Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta-analysis. Metab Syndr Relat Disord 2014; 12: 31-42
  12. Pezeshkian M, Mahtabipour MR. Epicardial and subcutaneous adipose tissue fatty acids profiles in diabetic and non-diabetic patients candidate for coronary artery bypass graft. Bioimpacts 2013; 3: 83-9
  13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2014 [http://www.goldcop